Cargando…

Moving beyond first-line treatment options for OCD

OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Seve...

Descripción completa

Detalles Bibliográficos
Autor principal: Paxos, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Psychiatric Pharmacists 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645290/
https://www.ncbi.nlm.nih.gov/pubmed/36405507
http://dx.doi.org/10.9740/mhc.2022.10.300
_version_ 1784826934465658880
author Paxos, Chris
author_facet Paxos, Chris
author_sort Paxos, Chris
collection PubMed
description OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails.
format Online
Article
Text
id pubmed-9645290
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Psychiatric Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-96452902022-11-18 Moving beyond first-line treatment options for OCD Paxos, Chris Ment Health Clin Psychopharmacology Pearls OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645290/ /pubmed/36405507 http://dx.doi.org/10.9740/mhc.2022.10.300 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Psychopharmacology Pearls
Paxos, Chris
Moving beyond first-line treatment options for OCD
title Moving beyond first-line treatment options for OCD
title_full Moving beyond first-line treatment options for OCD
title_fullStr Moving beyond first-line treatment options for OCD
title_full_unstemmed Moving beyond first-line treatment options for OCD
title_short Moving beyond first-line treatment options for OCD
title_sort moving beyond first-line treatment options for ocd
topic Psychopharmacology Pearls
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645290/
https://www.ncbi.nlm.nih.gov/pubmed/36405507
http://dx.doi.org/10.9740/mhc.2022.10.300
work_keys_str_mv AT paxoschris movingbeyondfirstlinetreatmentoptionsforocd